Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review
- 7 April 2025
- journal article
- review article
- Published by Wiley in Reviews in Medical Virology
- Vol. 35 (3) , e70035
Abstract
Both health and economic burdens of dengue virus (DENV), as an increasingly prevalent pathogen and global threat, exist in endemic regions. Vaccination is a key strategy in decreasing dengue morbidity and mortality. This systematic review assesses the efficacy, immune response and safety of dengue vaccines (Qdenga (TAK‐003) and Dengvaxia (CYD‐TDV)) in adolescents against the need for evidence‐based data for dengue vaccination strategies. We performed a systematic search of six databases (Scopus, PubMed, Web of Science, Cochrane, clinical trials. gov, and MEDLINE) for studies published until October 2024. A total of 482 articles were identified, 32 studies met the inclusion criteria after removing duplicates and title and abstract screening. Immunogenicity and safety profiles for both vaccines. TAK‐003 showed high seropositivity rates with all of the four DENV serotypes, especially for DENV‐2, with sustained antibody responses 3 years after vaccination. CYD‐TDV induced neutralising antibodies with balanced activity, but such an immune response was most efficient in individuals with baseline seropositivity, for whom greater efficacy was observed. Most adverse events were mild to moderate, such as transitory pain at the injection site and headache, while serious adverse events were rare and did not correlate with vaccination. Nonetheless, specific issues regarding serotype‐unique efficacy variations and the threat of vaccine‐induced immune enhancement in seronegative groups contribute to worry. These findings highlighted the importance of TAK‐003 and CYD‐TDV in reducing the impact of dengue, especially in endemic regions. Ongoing research is essential to refine vaccine deployment strategies, optimise protection across diverse populations, and address outstanding concerns regarding long‐term immunity and safety in seronegative individuals.Keywords
This publication has 44 references indexed in Scilit:
- Time-course of the tDCS antidepressant effect: An individual participant data meta-analysisProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2023
- Dengue fever and dengue virus in the People's Republic of ChinaReviews in Medical Virology, 2021
- Oral health care providers should be administering vaccinesOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021
- Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trialVaccine, 2020
- Designing effective control of dengue with combined interventionsProceedings of the National Academy of Sciences, 2020
- Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and AdolescentsNew England Journal of Medicine, 2019
- Dengue vaccination during pregnancy – An overview of clinical trials dataVaccine, 2018
- Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinateVaccine, 2016
- Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised studyVaccine, 2015
- Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USAVaccine, 2013